“Pharmaceutical industry innovations are first and for most about discovery of new molecules for the treatment of severe diseases” Natalya Malykh says

05.10.2021

Natalya Malykh, Vice President for Business Development of the Pharmasyntez Group of Companies, outlined issues of innovations and solutions the company uses in its everyday activities.

On October 5, a discussion session entitled Innovations In Pharma: First, Next Or Never was held at the BIOTECHMED forum. It was moderated by Aleksey Alekhin, advisor to the Minister of Industry and Trade. The discussion was focused on a complex process of innovations in the pharmaceutical industry. Speakers gave their opinions on ways of improving cooperation between research centers with industrial partners and discussed potential incentives for inducing innovations.

Natalya Malykh suggested the following ways to solve the issue of innovations representing a pharmaceutical company opinion:

To establish venture funds with state participation;
To join the efforts of the pharmaceutical industry and schools of thought;
To raise the profile of research and development projects;
And, what is the most crucial, to introduce a comprehensive expert review involving a doctor, researcher, manufacturer, developer, regulatory body, and an industrial partner.

“We had such experience before our original drug product entered into the clinical stage of development. We had a comprehensive expert evaluation of clinical trial design: we invited medical experts, developers, researchers and regulatory authority representatives. That approach turned out to be highly effective. We wish such expert reviews were held on a regular basis,” the Vice President noted.